ReviewCellular & molecular biology letters2026
Targeting dormant cancer cells: ferroptosis as a precision therapeutic strategy.
Review in Cellular & molecular biology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Dormant cancer cells are a significant source of cancer recurrence and metastasis and exhibit robust resistance to conventional therapies. Therefore, the exploration of novel therapeutic strategies to eliminate these cells has become a hot topic in cancer research. Ferroptosis, a newly identified form of regulated cell death, has garnered considerable attention in the field of cancer therapy in recent years. As a novel form of regulated cell death, the core mechanism of ferroptosis lies in the accumulation of intracellular iron and the induction of lipid peroxidation. Oxidative stress, the transforming growth factor-β (TGF-β) signaling pathway, autophagy, and lipid metabolism play dual roles in the survival of dormant cancer cells and the process of ferroptosis, influencing the response of dormant cancer cells to ferroptosis. These complex molecular mechanisms form a regulatory network between ferroptosis and dormant cancer cells, which holds significant implications for the development of future anti-tumor therapeutic strategies. This review synthesizes current evidence on targeting ferroptosis to eliminate dormant cancer cells, positions ferroptosis as a precision modality against dormant cancer cells, and discusses its therapeutic promise as a conceptual framework for developing next-generation anti-tumor strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.